Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

SGLT2 Inhibitor Class (multi-agent)

MARKETED

SGLT2 inhibitor (class-wide)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

SGLT2 Inhibitor Class (multi-agent) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
SGLT2 Inhibitor Class (multi-agent) MARKETED
Safety signals Decrease
Moderate evidence

A network meta-analysis of randomised outcome trials found SGLT2 inhibitors significantly reduce incident gout while GLP-1 RAs and DPP-4 inhibitors are neutral - the...

Wang A, Shi W, Zhang N, Tang H, Feng X. Newer glucose-lowering drugs and risk of gout: a ... Source
Full findingA network meta-analysis of randomised outcome trials found SGLT2 inhibitors significantly reduce incident gout while GLP-1 RAs and DPP-4 inhibitors are neutral - the contrast pole showing a genuinely uricosuric, gout-protective class distinct from GLP-1 RAs.
PopulationNetwork meta-analysis (Wang et al., 22 randomised placebo-controlled outcome trials, 173,498 patients with/without T2D).
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsIncluded for the SGLT2i-vs-GLP-1 contrast (the gout-protective comparator pole), not as a GLP-1/retatrutide claim. Indirect (network) comparisons between drug classes; gout a secondary outcome across heterogeneous CVOTs. Academic network meta-analysis.
Comparatorsplacebo; GLP-1 receptor agonist; DPP-4 inhibitor